Skip to main content
Beijing Science Sun Pharmaceutical Co.,LTD. logo

Beijing Science Sun Pharmaceutical Co.,LTD. — Investor Relations & Filings

Ticker · 300485 ISIN · CNE100002110 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,199 across all filing types
Latest filing 2026-03-30 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300485

About Beijing Science Sun Pharmaceutical Co.,LTD.

https://www.ssyy.com.cn

Beijing Science Sun Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and marketing of biochemical medicines. The company focuses on therapeutic areas including cardiovascular and cerebrovascular diseases, immune regulation, and nervous system disorders. Its product portfolio primarily consists of injections and lyophilized powders, with key offerings such as Monosialotetrahexosylganglioside Sodium Injection, Thymopentin for injection, and various enzyme-based treatments. The company utilizes advanced biochemical extraction and purification technologies to develop high-quality pharmaceutical products. It maintains modern production facilities compliant with Good Manufacturing Practice (GMP) standards, aiming to provide effective clinical solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement by Beijing Saisheng Pharmaceutical Co., Ltd. regarding the 2025 annual profit distribution plan. It includes details about the board meeting approving the plan, audited net profits, dividend distribution per share, and compliance with regulatory guidelines. The document is relatively short (1999 characters) and focuses on the profit distribution proposal rather than presenting full financial statements or comprehensive financial performance data. It is a formal announcement of a dividend plan, which aligns with the category of Notice of Dividend Amount (DIV). There is no indication that this is a full annual report or interim report, nor is it a simple publication announcement or certification. Therefore, the appropriate classification is DIV with high confidence.
2026-03-30 Chinese
董事会审计委员会对会计师事务所2025年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the external audit firm for the fiscal year 2025. It discusses the audit firm's qualifications, the audit process, communication with the audit firm, and the audit report issued for the 2025 annual financial statements. The document references the audit report and the annual report but does not contain the full annual report or the audit report itself. It is a supervisory and evaluative report on the audit firm's work rather than the audit report or annual report itself. Given the content focuses on audit oversight and evaluation, this fits the category of Audit Report / Information (AR). The document length is 2123 characters, which is relatively short but contains substantive content about audit evaluation, not just an announcement or certification. Therefore, the classification is AR with high confidence.
2026-03-30 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed financial summary table related to non-operating fund occupation and other related party fund transactions for the year 2025. It includes accounting details, balances, and interest amounts, and it is approved by the company's board meeting. The document is not a full annual or interim report but a specific financial disclosure related to related party transactions and fund usage. It is not an announcement or a brief summary but a specific report on financial dealings. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure of related party transactions and fund usage, not a full financial report or other specific category.
2026-03-30 Chinese
关于续聘公司2026年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2026. It details the audit firm's credentials, independence, past performance, and the approval process by the board and audit committee. The document does not contain any financial statements or audit results but is a formal notice about the selection of the audit institution for the upcoming year. This fits the category of an Audit Report / Information announcement, specifically about the audit firm appointment rather than the audit report itself. The document length is under 5,000 characters and is an announcement, not the audit report or financial statements. Therefore, the appropriate classification is AR (Audit Report / Information).
2026-03-30 Chinese
第五届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 13th meeting of the 5th Board of Directors of Beijing Saisheng Pharmaceutical Co., Ltd. It includes multiple agenda items such as approval of the general manager's work report, the board's annual report, the financial statements for 2025, the annual report, profit distribution plan, internal control self-evaluation report, auditor reappointment, remuneration plans for directors and senior management, financial assistance extension to a subsidiary, and other governance matters. The document repeatedly states that the detailed reports and documents are published separately on the official disclosure website (China Securities Regulatory Commission designated site). The document is a formal board meeting resolution announcement, not the actual reports themselves. It also includes voting results and procedural details about the board meeting. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document is not a full annual report, audit report, or financial statement, but a board meeting resolution announcement. The document length is 3634 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2026-03-30 Chinese
非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding non-operating fund occupation and other related party fund transactions for Beijing SaiSheng Pharmaceutical Co., Ltd. It includes a summary table of these transactions for the fiscal year 2025. The document is addressed to an accounting firm and references an audit report for the 2025 financial statements. It is a detailed disclosure related to regulatory requirements on fund occupation and related party transactions, including audit confirmation and management responsibility statements. The document is not a full annual report, earnings release, or management discussion but a standalone audit-related disclosure focusing on specific financial compliance and audit results. It fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report with accounting and audit details, not the full annual report or a simple announcement. The document length is under 5,000 characters but contains substantive audit and financial data, so it is not a mere announcement or certification. Therefore, the correct classification is AR with high confidence.
2026-03-30 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.